XML 80 R17.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2019
Intangible Assets, Net (Excluding Goodwill) [Abstract] |
Intangible Assets | INTANGIBLE ASSETS The following table summarizes our intangible assets, net (in millions):
|  | December 31, 2019 |  | December 31, 2018
|  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Foreign Currency Translation Adjustment |  | Net Carrying Amount
Finite-lived assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset - sofosbuvir |  | $ | 10,720 |  |  | $ | (4,253 | ) |  | $ | — |  |  | $ | 6,467 |  |  | $ | 10,720 |  |  | $ | (3,554 | ) |  | $ | — |  |  | $ | 7,166 |
Intangible asset - axicabtagene ciloleucel (DLBCL) |  | 6,200 |  |  | (761 | ) |  | — |  |  | 5,439 |  |  | 6,200 |  |  | (416 | ) |  | — |  |  | 5,784 |
Intangible asset - Ranexa |  | 688 |  |  | (688 | ) |  | — |  |  | — |  |  | 688 |  |  | (678 | ) |  | — |  |  | 10 |
Other |  | 1,098 |  |  | (454 | ) |  | (6 | ) |  | 638 |  |  | 1,096 |  |  | (359 | ) |  | (3 | ) |  | 734 |
Total finite-lived assets |  | 18,706 |  |  | (6,156 | ) |  | (6 | ) |  | 12,544 |  |  | 18,704 |  |  | (5,007 | ) |  | (3 | ) |  | 13,694 |
Indefinite-lived assets - IPR&D |  | 1,247 |  |  | — |  |  | (5 | ) |  | 1,242 |  |  | 2,047 |  |  | — |  |  | (3 | ) |  | 2,044 |
Total intangible assets |  | $ | 19,953 |  |  | $ | (6,156 | ) |  | $ | (11 | ) |  | $ | 13,786 |  |  | $ | 20,751 |  |  | $ | (5,007 | ) |  | $ | (6 | ) |  | $ | 15,738 |
Aggregate amortization expense related to finite-lived intangible assets was $1.1 billion, $1.2 billion and $912 million for the years ended December 31, 2019, 2018 and 2017, respectively, and is primarily included in Cost of goods sold on our Consolidated Statements of Income. Amounts capitalized as IPR&D are subject to impairment testing until the completion or abandonment of the associated R&D efforts. During the fourth quarter of 2019, we performed quantitative impairment testing of our IPR&D intangible assets using a probability-weighted income approach that discounts expected future cash flows to present value. The estimated net cash flows were discounted using a discount rate of 9.5%, which is based on the estimated weighted-average cost of capital for companies with profiles similar to our profile and represents the rate that market participants would use to value the intangible assets. The discounted cash flow models used in valuing these intangible assets also require the use of Level 3 fair value measurements and inputs including estimated revenues, costs, and probability of technical and regulatory success. In comparison to the 2018 assessment, we used lower estimated revenues in 2019 due to changes in the estimated market opportunities as new therapies or combinations of existing therapies were approved. The lower estimated revenues reduced the fair value of the IPR&D intangible assets, primarily related to axicabtagene ciloleucel for the treatment of iNHL, below carrying value resulting in the recognition of an impairment charge of $800 million, which was recorded within Research and development expenses on our Consolidated Statements of Income. In 2018, we concluded that the KITE-585 program did not justify further efforts based on the totality of the clinical data gathered and discontinued the program. As a result, the carrying value of the IPR&D relating to the KITE-585 program was written down to zero and we recorded an impairment charge of $820 million within Research and development expenses on our Consolidated Statements of Income. No IPR&D impairment charges were recorded in 2017. The following table summarizes the estimated future amortization expense associated with our finite-lived intangible assets as of December 31, 2019 (in millions):
Fiscal Year | Amount
2020 | $ | 1,125 |
2021 | 1,124 |
2022 | 1,124 |
2023 | 1,124 |
2024 | 1,125 |
Thereafter | 6,922 |
Total | $ | 12,544 |

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration